Indian biotech company says approved Covid shot trials 'honest'
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
SUNDAY, MAY 29, 2022
SUNDAY, MAY 29, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Indian biotech company says approved Covid shot trials 'honest'

Coronavirus chronicle

Reuters
04 January, 2021, 10:00 pm
Last modified: 04 January, 2021, 10:05 pm

Related News

  • Indian drug regulator okays Covaxin for 6-12 year olds, Corbevax for 5-12 bracket
  • India gives nod to Bharat Biotech for intranasal Covid booster doses
  • India's Bharat Biotech says Covaxin booster shot neutralises Omicron
  • Bharat Biotech gets approval to test nasal Covid-19 shot as booster - report
  • Bharat Biotech to produce 1 billion nasal vaccines in 2022

Indian biotech company says approved Covid shot trials 'honest'

Hyderabad-based Bharat Biotech had carried out "200 percent honest clinical trials", Krishna Ella, chairman and managing director, told reporters an online address on Monday

Reuters
04 January, 2021, 10:00 pm
Last modified: 04 January, 2021, 10:05 pm
Photo: Reuters
Photo: Reuters

A top executive at an Indian biotechnology company defended its Covid-19 vaccine candidate, approved for emergency use by the government, and said it will produce efficacy data from late-stage trials by March.

The vaccine, COVAXIN, received emergency use approval from India's drugs regulator on Sunday, but the move faced questions after the regulator took the step without publishing information about its efficacy.

Hyderabad-based Bharat Biotech had carried out "200 percent honest clinical trials", Krishna Ella, chairman and managing director, told reporters an online address on Monday.

Ella highlighted the company's experience and expertise in producing vaccines, its numerous patents and its presence in 123 countries.

The approval for COVAXIN, jointly developed with a government institute, was hailed by Prime Minister Narendra Modi and his ministers as a success in India's self-reliance push.

Efficacy data from the company's ongoing late-stage trial should be available by March, Ella said.

Health Minister Harsh Vardhan clarified on Twitter on Sunday that the emergency use approval for COVAXIN was "in clinical trial mode", wherein all recipients of the vaccine would be tracked and monitored as if they were in trial.

The company is also investing in four manufacturing facilities and is planning to make around 200 million doses in Hyderabad and 500 million doses in other cities this year. The company has 20 million available doses so far.

India has the second-highest number of coronavirus infections in the world, though cases have been steadily falling since a peak in September.

India also approved the use of a vaccine developed by AstraZeneca and Oxford University which will be the lead vaccine in the country's immunisation programme.

Top News / South Asia

Bharat Biotech

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Central bankers’ refusal to embark into ‘hard helicopter money’ experiment have been a good idea. Photo: Reuters
    Interbank exchange rate for dollar set at Tk89
  • A Regio regional passenger train operated by Deutsche Bahn AG travels on a bridge in Berlin. Photographer: Krisztian Bocsi/Bloomberg
    Why Germany is offering a summer of cheap trains
  • Patients opting to delay crucial treatment amid rising costs
    Patients opting to delay crucial treatment amid rising costs

MOST VIEWED

  • A woman wearing a face mask crosses a road at the Central Business District (CBD), amid the coronavirus disease (Covid-19) outbreak in Beijing, China May 10, 2022. REUTERS/Carlos Garcia Rawlins
    Shanghai to lift 'unreasonable' curbs on firms, Beijing eases restrictions
  • Photo: Collected
    US doctors reconsider Pfizer's Paxlovid for lower-risk Covid patients
  • People wearing protective face masks walk on a street, following new cases of the coronavirus disease (Covid-19), in Shanghai, China August 25, 2021. REUTERS/Aly Song
    'Tomorrow will be better': Shanghai inches towards Covid re-opening
  • North Korea says new fever cases under 100,000 as virus fight heats up
    North Korea says new fever cases under 100,000 as virus fight heats up
  • People in protective suits cross a street during lockdown, amid the coronavirus disease (COVID-19) pandemic, in Shanghai, China, May 26, 2022. REUTERS/Aly Song
    Shanghai heading out of lockdown but China still lost in economic gloom
  • A woman wearing a face mask crosses a road at the Central Business District (CBD), amid the coronavirus disease (Covid-19) outbreak in Beijing, China May 10, 2022. REUTERS/Carlos Garcia Rawlins
    Tightening Covid net, Beijing deals out punishments, stark warnings

Related News

  • Indian drug regulator okays Covaxin for 6-12 year olds, Corbevax for 5-12 bracket
  • India gives nod to Bharat Biotech for intranasal Covid booster doses
  • India's Bharat Biotech says Covaxin booster shot neutralises Omicron
  • Bharat Biotech gets approval to test nasal Covid-19 shot as booster - report
  • Bharat Biotech to produce 1 billion nasal vaccines in 2022

Features

Central bankers’ refusal to embark into ‘hard helicopter money’ experiment have been a good idea. Photo: Reuters

Venice has a 400-year-old Covid monetary lesson

2h | Panorama
Aiman R Khan. Illustration: TBS

Why ‘marry your rapist’ court orders are not always what they seem

5h | Thoughts
Photo: Collected

Top 3 The Ordinary products that give extraordinary results

7h | Mode
Photo: Courtesy

KVN Beauty: Channel your inner Bangalee baddie

7h | Mode

More Videos from TBS

Paper industry worth thousands of crores in Bogura

Paper industry worth thousands of crores in Bogura

1h | Videos
Photo: TBS

Tips to help you become a successful lawyer

8h | Videos
Photo: TBS

Harassment over 'indecent clothing': Women gather at Narsingdi railway station to protest, show solidarity

8h | Videos
People bid adieu to Abdul Gaffar Chowdhury

People bid adieu to Abdul Gaffar Chowdhury

8h | Videos

Most Read

1
Bangladesh Bank GM, DGM’s designation changed
Banking

Bangladesh Bank GM, DGM’s designation changed

2
Corporates go cashless…tax cut on cards
NBR

Corporates go cashless…tax cut on cards

3
Photo: Courtesy
Panorama

Misfit Technologies: A Singaporean startup rooted firmly in Bangladesh

4
British International Investment (BII) CEO Nick O’Donohoe. Illustration: TBS
Economy

BII to invest $450m in Bangladesh in 5 years

5
Representational image. Picture: Pixabay
Economy

Govt raises regulatory duty to discourage imports of 130 products

6
Photo: Collected
Industry

Spanish recycled cotton producer opens new facility in Bangladesh

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab